FDA approves 6 new blood cancer treatments in the last 3 months
Since June 2020 the FDA has approved 6 new blood cancer treatments and expanded the use of an already available treatment. Sadly none are approved for use in Australia yet. This highlights how important it is that we continue to fund research through clinical trials to provide access to next generation treatments ahead of Australian registration. It is Snowdome’s mission to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives. You are helping this mission with every word of support and donation to our cause. Thank you.
For information on the treatments approved in the USA please see below.
FDA approved the first anti-BCMA therapy (belantamab mafodotin-blmf) for the treatment of adult patients with R/R multiple myeloma who have received at least 4 prior therapies. Currently not approved for use in Australia
FDA approved the expansion of carfilzomib in combination with daratumumab plus dexamethasone for R/R multiple myeloma. Carfilzomib is approved in Australia but currently only for use in combination with dexmethasome or lenalidomide, therefore an expansion in the label is still required in Australia.
FDA approved a new CAR-T cell therapy (brexucabtagene autoleucel) for Mantle Cell Lymphoma. Currently not approved for use in Australia.
FDA approved tazemetostat for R/R follicular lymphoma. Currently not approved for use in Australia.
FDA approved gemtuzumab ozogamicin for CD33 positive AML in paediatric patients. Registered in Australia but awaiting final approval and funding.